Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK3 | O75914 | 1/20 | 0.61 |
| ▸ | PAK4 | O96013 | 1/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.61 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.61 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.61 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.61 |
| ▸ | WEE1 | P30291 | 2/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.55 |
| ▸ | SRC | P12931 | 9/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.55 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.55 |
| ▸ | STAT5A | P42229 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252509 | 0.97 | PAK3 (0.60) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2248740 | 0.93 | WEE1 (0.55) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2252944 | 0.91 | WEE1 (0.59) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2254302 | 0.90 | WEE1 (0.56) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL13981943 | 0.89 | PAK3 (0.54) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2252528 | 0.89 | WEE1 (0.54) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2251348 | 0.89 | WEE1 (0.58) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2249939 | 0.88 | WEE1 (0.54) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL2251720 | 0.88 | FGFR1 (0.66) | WEE1FGFR1SRCEGFRPDGFRB | |
| SCHEMBL2247993 | 0.88 | FGFR1 (0.59) | WEE1FGFR1SRCEGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PAK3 79/4885PAK4 95/4885LIMK1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.